Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | DRD4 | P21917 | 3/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30380101 | 0.89 | SIGMAR1 (0.61) | DRD2SIGMAR1 | |
| SCHEMBL16373187 | 0.88 | DRD2 (0.44) | DRD2SIGMAR1DRD4BCHEACHE | |
| SCHEMBL31687472 | 0.88 | SIGMAR1 (0.61) | SIGMAR1BCHEACHEACKR3 | |
| SCHEMBL16335778 | 0.86 | SIGMAR1 (0.56) | DRD2SIGMAR1DRD4DRD3BCHE | |
| SCHEMBL16340111 | 0.83 | DRD2 (0.60) | DRD2SIGMAR1DRD4 | |
| SCHEMBL21070067 | 0.78 | ACHE (0.56) | SIGMAR1BCHEACHEACKR3 | |
| SCHEMBL21069692 | 0.78 | ACHE (0.56) | SIGMAR1BCHEACHEACKR3 | |
| SCHEMBL8254760 | 0.76 | DRD2 (0.64) | DRD2SIGMAR1 | |
| SCHEMBL3151917 | 0.76 | SIGMAR1 (0.48) | SIGMAR1ACKR3 | |
| SCHEMBL31687499 | 0.76 | SIGMAR1 (0.58) | SIGMAR1ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3013824-B1 | CARBOLINE COMPOUNDS USABLE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | ALZPROTECT (FR) | 2018-05-16 | — | — | EP | disclosed |
| US-9714245-B2 | Carboline compounds usable in the treatment of neurodegenerative diseases | ALZPROTECT (FR) | 2017-07-25 | — | — | US | disclosed |
| US-9714245-B2 | Carboline compounds usable in the treatment of neurodegenerative diseases | ALZPROTECT (FR) | 2017-07-25 | — | — | US | disclosed |
| US-9714245-B2 | Carboline compounds usable in the treatment of neurodegenerative diseases | ALZPROTECT (FR) | 2017-07-25 | — | — | US | disclosed |
| US-20160152610-A1 | Carboline Compounds Usable in The Treatment of Neurodegenerative Diseases | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-06-02 | — | — | US | disclosed |
| US-20160152610-A1 | Carboline Compounds Usable in The Treatment of Neurodegenerative Diseases | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-06-02 | — | — | US | disclosed |
| US-20160152610-A1 | Carboline Compounds Usable in The Treatment of Neurodegenerative Diseases | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-06-02 | — | — | US | disclosed |
| WO-2014207240-A1 | CARBOLINE COMPOUNDS USABLE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | ALZPROTECT (FR) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014207241-A1 | NEW Na-SUBSTITUTED CARBOLINE COMPOUNDS USABLE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ALZPROTECT (FR) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014207241-A1 | NEW Na-SUBSTITUTED CARBOLINE COMPOUNDS USABLE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ALZPROTECT (FR) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152610-A1 | Carboline Compounds Usable in The Treatment of Neurodegenerative Diseases | SNCA, PARK7, HTT | DRD2 454/4885SIGMAR1 923/4885DRD4 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.